Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery

被引:0
|
作者
Li, Li [1 ]
Huang, Jia-Ling [1 ]
Liu, Qi-Cai [2 ]
Wu, Pei-Hong [1 ]
Liu, Ran-Yi [1 ]
Zeng, Yi-Xin [1 ]
Huang, Wen-Lin [1 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] Guangzhou Med Coll, Expt Med Res Ctr, Guangzhou 510182, Guangdong, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the expression of adenovirus-mediated human endostatin (Ad/hEndo) gene transfer and its effect on the growth of hepatocellular carcinoma (HCC) BEL-7402 xenografted tumors. METHODS: Immunohistochemistry analysis with an anti-endostatin antibody was preformed to detect endostatin protein expression in HCC BEL-7402 cells infected with Ad/hEndo. MTT assay was used to investigate the effects of Ad/hEndo on proliferation of human umbilical vein endothelial cells (HUVEC). Intra-tumoral injections of 1x10(9) pfu Ad/hEndo was given to treat BEL-7402 xenografted tumors in nude mice once weekly for 6 wk. Mice received injections of Ad/LacZ and DMEM were regarded as control groups. After intra-turmoral administration with Ad/hEndo, the endostatin mRNA expression in tumor tissue was analyzed by Northern blotting, and plasma endostatin levels were determined using enzyme-linked immunosorbent assay (ELISA). RESULTS: High level expression of endostatin gene was detected in the infected HCC BEL-7402 cells. Ad/hEndo significantly inhibited HUVEC cell proliferation by 57.2% at a multiplicity of infection (MOI) of 20. After 6-week treatment with Ad/hEndo, the growth of treated tumors was inhibited by 46.50% compared to the Ad/LacZ control group (t=2.729, P<0.05) and by 48.56% compared to the DMEM control group (t=2.485, P<0.05). The ratio of mean tumor volume in treated animals to mean tumor volume in the control animals (T:C ratio) was less than 50% after 24 d of treatment. Endostatin mRNA in tumor tissue was clearly demonstrated as a band of approximately 1.2 kb, which was the expected size of intact and functional endostatin. Plasma endostatin levels peaked at 87.52 +/- 8.34 ng/mL at d 3 after Ad/hEndo injection, which was significantly higher than the basal level (12.23 +/- 2.54 ng/mL). By d 7, plasma levels dropped to nearly half the peak level (40.34 +/- 4.80 ng/mL). CONCLUSION: Adenovirus-mediated human endostatin gene can successfully express endogenous endostatin in vitro and in vivo, and significantly inhibit the growth of BEL-7402 xenografted liver tumors in nude mice.
引用
收藏
页码:1867 / 1871
页数:5
相关论文
共 50 条
  • [41] In utero cardiac gene transfer via intraplacental delivery of recombinant adenovirus
    Woo, YJ
    Raju, GP
    Swain, JL
    Richmond, ME
    Gardner, TJ
    BaliceGordon, RJ
    CIRCULATION, 1997, 96 (10) : 3561 - 3569
  • [42] Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy
    Sheldon, Yarrow
    Yoo, Byung-Chun
    Kmiec, Eric
    Petrelli, Nicholas
    Tiesi, Gregory
    Warner, Shelley
    HUMAN GENE THERAPY, 2023, 34 (7-8) : 314 - 324
  • [43] Construction of a new recombinant adenovirus:: possible uses in gene therapy
    Peran, M.
    Velez, C.
    Boulaiz, H.
    Marchal, J. A.
    Rodriguez-Serrano, F.
    Melguizo, C.
    Prados, J. C.
    Martinez-Amat, A.
    Hita, F.
    Caba, O.
    Aranega, A.
    JOURNAL OF ANATOMY, 2007, 210 (05) : 625 - 625
  • [44] Characterization and quality control of recombinant adenovirus vectors for gene therapy
    Roitsch, C
    Achstetter, T
    Benchaibi, M
    Bonfils, E
    Cauet, G
    Gloeckler, R
    L'hôte, H
    Keppi, E
    Nguyen, M
    Spehner, D
    Van Dorsselaer, A
    Malarme, D
    JOURNAL OF CHROMATOGRAPHY B, 2001, 752 (02): : 263 - 280
  • [45] Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus
    Arland, V
    Barral, DC
    Zeng, Y
    Brunsmann, F
    Maguire, AM
    Seabra, MC
    Bennett, J
    VISION RESEARCH, 2003, 43 (08) : 919 - 926
  • [46] Gene therapy with recombinant adenovirus in lung cancer: Final results of the French phase I study
    Escudier, B
    LeCesne, A
    Farace, F
    Gautier, E
    Saulnier, P
    Zitvogel, L
    Schatz, C
    Lamy, D
    LeChevalier, T
    Tursz, T
    CANCER GENE THERAPY, 1997, 4 (06) : O35 - O35
  • [47] Cancer gene therapy: 'Delivery, delivery, delivery'
    Greco, O
    Scott, SD
    Marples, B
    Dachs, GU
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 : D1516 - D1524
  • [48] Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment
    Xu, Fuguo
    Ma, Qingyong
    Sha, Huanchen
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2007, 24 (05): : 445 - 492
  • [49] Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy:: Selective inhibitor of angiogenesis and hypoxic tumor growth
    Li, X
    Fu, GF
    Fan, YR
    Liu, WH
    Liu, XJ
    Wang, JJ
    Xu, GX
    CANCER GENE THERAPY, 2003, 10 (02) : 105 - 111
  • [50] Enhancement of gene delivery to cancer cells by a retargeted adenovirus
    Oh, KS
    Engler, JA
    Joung, I
    JOURNAL OF MICROBIOLOGY, 2005, 43 (02) : 179 - 182